Recruiting studies: Oligoprogression

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192 PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697 Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827 A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProg
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT06367972 Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metast
Phase 2 · 1 location(s) · Yale University · NCT04974671 The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304 Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Posit
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06260033 COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the
Phase 2 · 7 location(s) · The Netherlands Cancer Institute · NCT05301881 Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058 Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT06585007 Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Phase 2 · 1 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT04989725 Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT06870942 LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
NA · 1 location(s) · University of California, Davis · NCT06103682 Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NA · 1 location(s) · University of California, Davis · NCT06103669 SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After
Phase 2 · 2 location(s) · The First Affiliated Hospital of Xiamen University · NCT06676722 Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Phase 3 · 75 location(s) · Canadian Cancer Trials Group · NCT06686771 Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06523673 A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07193641 Stereotactic Magnetic Resonance Guided Radiation Therapy
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT04115254 Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell L
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT03546829 Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NA · 2 location(s) · Mayo Clinic · NCT06055881 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04892953 Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
NA · 1 location(s) · University Health Network, Toronto · NCT07112170 Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Ster
NA · 15 location(s) · Centre Francois Baclesse · NCT05102747 Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
NA · 1 location(s) · British Columbia Cancer Agency · NCT06918951 SBRT in HCC With Oligoprogression on First-line Immunotherapy
NA · 1 location(s) · Chinese University of Hong Kong · NCT06434480 Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06601296 Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/
NA · 14 location(s) · Robert Olson · NCT05784428 Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
NA · 1 location(s) · Sunnybrook Health Sciences Centre · NCT04838899 Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
NA · 1 location(s) · University of California, Davis · NCT06101277

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.